"RSV Prevention: A Game-Changing Drug Approved for Infants"

The US FDA has approved an antibody injection called Nirsevimab to protect newborns from respiratory syncytial virus (RSV), while two new RSV vaccines have been approved for adults aged 60 and older. The CDC is also considering an RSV vaccine for expectant individuals. RSV is a common virus that can cause severe symptoms and hospitalizations, particularly in young children and older adults. The vaccines for older adults have shown high effectiveness and durability, with availability expected by the end of July. The RSV vaccine can be administered alongside other vaccines, and the antibody injection is awaiting CDC recommendations for newborns. These developments provide important tools for preventing severe RSV disease.